Capmatinib (INCB28060, INCB-28060, INC280, INC-280)，又称卡马替尼或苯扎米特，是一种可口服的、ATP竞争性c-MET抑制剂，IC₅₀为0.13 nM，有抗肿瘤活性。c-MET是原癌基因，又称肝细胞生长因子受体，在多种肿瘤中过表达，在驱动肿瘤细胞生长和存活中发挥关键作用。

参考文献

1.Liu X, et al. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. Clin Cancer Res. 2011 Nov 15;17(22):7127-38.

2.Baltschukat S, et al. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation. Clin Cancer Res. 2019 May 15;25(10):3164-3175.

冰袋运输。粉末直接保存于-20℃，有效期3年。建议分装后-20℃干燥保存，避免反复冻融。